# Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma (RATIONALE-306): a global, randomised, placebo-controlled, phase 3 study

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/tislelizumab-plus-chemotherapy-versus-placebo-plus-chemotherapy-as-first-line/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Jianming Xu,Ken Kato,Eric Raymond,Richard Hubner,Yongqian Shu,Yueyin Pan,Sook Ryun Park,Lu Ping,Yi Jiang,Jingdong Zhang,Xiaohong Wu,Yuanhu Yao,Lin Shen,Takashi Kojima,Evgeny Gotovkin,Ryu Ishihara,Lucjan Wyrwicz,Eric Van Cutsem,Paula Jiménez‐Fonseca,Chen‐Yuan Lin,Lei Wang,Jingwen Shi,Liyun Li,Harry H. Yoon |
| Citations | 312 |
| DOI | 10.1016/s1470-2045(23)00108-0 |
| Fields | Medicine |
| Open Access | false |
| OA Status | closed |
| OpenAlex ID | https://openalex.org/W4366144760 |
| PMID | 37080222 |
| Type | article |
| Year | 2023 |

## Paper authors

- [Yueyin Pan](https://scholariq.org/researchers/yueyin-pan/)

## Paper journal

- [The Lancet Oncology](https://scholariq.org/journals/the-lancet-oncology/)

## Paper primary topic

- [Esophageal Cancer Research and Treatment](https://scholariq.org/topics/esophageal-cancer-research-and-treatment/)

## Paper topics

- [Esophageal Cancer Research and Treatment](https://scholariq.org/topics/esophageal-cancer-research-and-treatment/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Colorectal and Anal Carcinomas](https://scholariq.org/topics/colorectal-and-anal-carcinomas/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.